Melinta Therapeutics

Melinta Therapeutics company information, Employees & Contact Information

High touch and big impact are trademarks of Melinta. We are nimble and agile without sacrificing our dedication to adding value everywhere we go. You see, the people of Melinta are believers. Woven into the fiber of our culture is tenacity, brilliance, resilience, excellence and courage. Nothing can weaken our resolve. We take each responsibility seriously, because when we make a move, it matters. Watch us as we grow. We are the company of the moment and the enterprise of the future. We’re unparalleled in our ability to meet the unmet needs of our patients, and we do so collaboratively. Because we believe the most diverse teams produce the most meaningful impact. We can’t wait to make legendary strides. Every step counts.

Company Details

Employees
168
Address
389 Interpace Pkwy,
Phone
(203) 624-5606
Email
in****@****nta.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Parsippany, New Jersey
Looking for a particular Melinta Therapeutics employee's phone or email?

Melinta Therapeutics Questions

News

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership Business Wire

CorMedix Completes Acquisition of Melinta Therapeutics - citybiz

CorMedix Completes Acquisition of Melinta Therapeutics citybiz

$300M Pharma Deal: CorMedix Acquires Melinta's 7-Drug Portfolio, Targets $350M Revenue by 2025 - Stock Titan

$300M Pharma Deal: CorMedix Acquires Melinta's 7-Drug Portfolio, Targets $350M Revenue by 2025 Stock Titan

Melinta Joins NHIA Future of Infusion Advisory Council - Business Wire

Melinta Joins NHIA Future of Infusion Advisory Council Business Wire

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company - GlobeNewswire

Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company GlobeNewswire

$300M CorMedix-Melinta Deal Creates Powerhouse with $335M Revenue Potential, 7 Acute Care Products - Stock Titan

$300M CorMedix-Melinta Deal Creates Powerhouse with $335M Revenue Potential, 7 Acute Care Products Stock Titan

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals - GlobeNewswire

Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals GlobeNewswire

Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products - Business Wire

Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products Business Wire

Melinta Therapeutics Appoints Fabrizio Tondolo, MD, as Vice President of Medical Affairs - citybiz

Melinta Therapeutics Appoints Fabrizio Tondolo, MD, as Vice President of Medical Affairs citybiz

Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer - Business Wire

Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer Business Wire

Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection) - Business Wire

Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection) Business Wire

Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID - Business Wire

Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID Business Wire

Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer - Business Wire

Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer Business Wire

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam - Business Wire

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam Business Wire

Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin) - Business Wire

Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin) Business Wire

Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio - Business Wire

Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio Business Wire

Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding - GlobeNewswire

Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding GlobeNewswire

Melinta Therapeutics Appoints Christine Ann Miller as CEO - citybiz

Melinta Therapeutics Appoints Christine Ann Miller as CEO citybiz

Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company - GlobeNewswire

Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company GlobeNewswire

CorMedix Announces Strategic Minority Investment in Talphera - Yahoo Finance

CorMedix Announces Strategic Minority Investment in Talphera Yahoo Finance

CorMedix Inc. Completes Enrollment in Phase III ReSPECT Study for REZZAYO® in Fungal Infection Prophylaxis, Topline Results Expected 2Q 2026 | CRMD Stock News - Quiver Quantitative

CorMedix Inc. Completes Enrollment in Phase III ReSPECT Study for REZZAYO® in Fungal Infection Prophylaxis, Topline Results Expected 2Q 2026 | CRMD Stock News Quiver Quantitative

CorMedix Inc. Reports Q3 2025 Pro Forma Net Revenue Exceeding $125 Million and Raises Full-Year Guidance to $375 Million - Quiver Quantitative

CorMedix Inc. Reports Q3 2025 Pro Forma Net Revenue Exceeding $125 Million and Raises Full-Year Guidance to $375 Million Quiver Quantitative

Major Clinical Trial Progress: CorMedix's REZZAYO Could Transform Blood and Marrow Transplant Care - Stock Titan

Major Clinical Trial Progress: CorMedix's REZZAYO Could Transform Blood and Marrow Transplant Care Stock Titan

Cempra and Melinta Announce Merger to Form Leading, - GlobeNewswire

Cempra and Melinta Announce Merger to Form Leading, GlobeNewswire

Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer | User | woonsocketcall.com - FinancialContent

Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer | User | woonsocketcall.com FinancialContent

At least $375M FY2025 guidance — CorMedix raises pro forma net revenue; Q3 pro forma >$125M - Stock Titan

At least $375M FY2025 guidance — CorMedix raises pro forma net revenue; Q3 pro forma >$125M Stock Titan

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team - The Manila Times

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team The Manila Times

FDA Approves New Intravenous, Oral Antibiotic for Skin Infections - Infectious Disease Advisor

FDA Approves New Intravenous, Oral Antibiotic for Skin Infections Infectious Disease Advisor

CorMedix Inc. Announces DefenCath Receives Innovative Technology Designation from Vizient - Quiver Quantitative

CorMedix Inc. Announces DefenCath Receives Innovative Technology Designation from Vizient Quiver Quantitative

Melinta Therapeutics and Eurofarma Laboratorios Enter into - GlobeNewswire

Melinta Therapeutics and Eurofarma Laboratorios Enter into GlobeNewswire

New Antibiotic Baxdela Gets FDA Approval - Medical Professionals Reference

New Antibiotic Baxdela Gets FDA Approval Medical Professionals Reference

DefenCath by CorMedix (NASDAQ: CRMD) receives Vizient Innovative Technology designation - Stock Titan

DefenCath by CorMedix (NASDAQ: CRMD) receives Vizient Innovative Technology designation Stock Titan

Melinta Therapeutics Announces Vabomere™ (meropenem and - GlobeNewswire

Melinta Therapeutics Announces Vabomere™ (meropenem and GlobeNewswire

Melinta Therapeutics and Hartford Hospital Demonstrate - GlobeNewswire

Melinta Therapeutics and Hartford Hospital Demonstrate GlobeNewswire

Melinta Therapeutics' Lead Candidate Delafloxacin Yields - GlobeNewswire

Melinta Therapeutics' Lead Candidate Delafloxacin Yields GlobeNewswire

Melinta Therapeutics Study Demonstrates Significant Burden - GlobeNewswire

Melinta Therapeutics Study Demonstrates Significant Burden GlobeNewswire

Melinta Therapeutics Demonstrates Potent In Vitro Activity - GlobeNewswire

Melinta Therapeutics Demonstrates Potent In Vitro Activity GlobeNewswire

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance - The Manila Times

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance The Manila Times

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath - The Manila Times

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath The Manila Times

Top Melinta Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant